Apyx Medical (APYX) Expected to Post Quarterly Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $13.1750 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06. The business had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. On average, analysts expect Apyx Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Apyx Medical Trading Up 3.5%

Shares of APYX stock traded up $0.14 during trading on Tuesday, hitting $4.33. 7,409 shares of the stock traded hands, compared to its average volume of 141,609. Apyx Medical has a 52-week low of $1.70 and a 52-week high of $5.08. The firm has a market capitalization of $181.26 million, a P/E ratio of -19.66 and a beta of 1.39. The firm’s fifty day moving average price is $4.23 and its 200-day moving average price is $3.94. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79.

Hedge Funds Weigh In On Apyx Medical

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in shares of Apyx Medical in the 3rd quarter valued at $28,000. Osaic Holdings Inc. acquired a new position in Apyx Medical during the second quarter worth $50,000. Franklin Resources Inc. acquired a new stake in Apyx Medical in the third quarter valued at $59,000. Hudson Bay Capital Management LP acquired a new position in shares of Apyx Medical during the 4th quarter worth $73,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Apyx Medical during the fourth quarter worth about $111,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on APYX. Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, HC Wainwright started coverage on shares of Apyx Medical in a research report on Monday, July 13th. They issued a “buy” rating and a $7.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.